BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto’s thyroiditis is a reliable assay
- 18 June 2013
- journal article
- research article
- Published by Springer Nature in Endocrine
- Vol. 45 (2) , 249-255
Abstract
Detection of BRAF mutation in cytology specimens has been proposed as a diagnostic adjunctive tool in evaluation of thyroid nodules with indeterminate cytology findings. Concurrent papillary thyroid carcinoma and Hashimoto’s thyroiditis (HT), a disease characterized by thyroid lymphocytic infiltration, is a frequent occurrence. A large lymphocytic infiltrate might reduce the sensitivity of methods employed to detect BRAF mutation in thyroid cytology specimens. To determine whether testing for BRAF mutational status in fine needle aspirates (FNA) is reliable also in the presence of HT lymphocytic infiltration, we assessed the BRAF status by direct sequencing and pyrosequencing in a series of FNAs with and without concomitant HT lymphocytic infiltration. We also performed the same assessment by pyrosequencing in the corresponding tissue samples. Pyrosequencing demonstrated to be more sensitive than direct sequencing. The percentage of mutant BRAF V600E alleles was higher in FNAs than in the corresponding tissues, probably because of the lower stromal contamination in FNA than in the sections. In the presence of lymphocytic infiltration, the percentage of mutant BRAF V600E alleles determined by pyrosequencing was higher in FNAs than in the corresponding tissue samples (P BRAF V600E in inconclusive FNAs was not hampered by thyroid lymphocytic infiltration. These results indicate that BRAF V600E assessment by pyrosequencing is a reliable assay useful to refine inconclusive cytology of thyroid nodules also in the presence of concurrent HT.Keywords
This publication has 36 references indexed in Scilit:
- SEREX: a promising approach for identification of thyroid cancer serological biomarkersClinical Endocrinology, 2013
- Intratumor BRAF V600E Heterogeneity and Kinase Inhibitors in the Treatment of Thyroid Cancer: A Call for ParticipationThyroid®, 2013
- The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysisEuropean Journal of Endocrinology, 2013
- BRAF V600E associates with cytoplasmatic localization of p27kip1 and higher cytokeratin 19 expression in papillary thyroid carcinomaEndocrine, 2012
- Thyroid surgery in geriatric patients: a literature reviewBMC Surgery, 2012
- B-RafV600Eand thrombospondin-1 promote thyroid cancer progressionProceedings of the National Academy of Sciences, 2010
- Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid CancerThyroid®, 2009
- BRAF Mutation in Papillary Thyroid Cancer: Pathogenic Role, Molecular Bases, and Clinical ImplicationsEndocrine Reviews, 2007
- Diagnostic Value of Differential Expression of CK19, Galectin-3, HBME-1, ERK, RET, and p16 in Benign and Malignant Follicular-Derived Lesions of the Thyroid: An Immunohistochemical Tissue Microarray AnalysisEndocrine Pathology, 2006
- Fine-Needle Aspiration of Thyroid Nodules: Past, Present, and FutureEndocrine Practice, 2004